Boston Scientific Corp (BSX)vsIntelligent Bio Solutions Inc. (INBS)
BSX
Boston Scientific Corp
$48.31
+2.43%
HEALTHCARE · Cap: $70.87B
INBS
Intelligent Bio Solutions Inc.
$2.44
-3.94%
HEALTHCARE · Cap: $6.77M
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 526668% more annual revenue ($20.61B vs $3.91M). BSX leads profitability with a 17.3% profit margin vs -296.8%. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
INBS
Hold38
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-27.8%
Fair Value
$37.33
Current Price
$48.31
$10.98 premium
Margin of Safety
-23.2%
Fair Value
$4.26
Current Price
$2.44
$1.82 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Reasonable price relative to book value
Revenue surging 45.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
No major concerns identified
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -170.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : INBS
The strongest argument for INBS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 45.5% demonstrates continued momentum.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : INBS
The primary concerns for INBS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
BSX profiles as a mature stock while INBS is a hypergrowth play — different risk/reward profiles.
INBS carries more volatility with a beta of 4.24 — expect wider price swings.
INBS is growing revenue faster at 45.5% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 38/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Intelligent Bio Solutions Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology firm specializing in the development of advanced diagnostic solutions and biomarker-driven technologies for drug abuse testing and monitoring. The company's innovative approach harnesses state-of-the-art scientific methodologies to deliver rapid and accurate testing options, enabling timely clinical decision-making and enhancing patient outcomes. As the demand for sophisticated diagnostic tools continues to rise, INBS is strategically positioned to lead the transformation of healthcare diagnostics, underscoring its commitment to improving healthcare quality and efficiency.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?